探索放射性标记纳米粒子在多模态癌症影像与诊疗中的创新进展
Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:3.5
分区:医学2区 / 肿瘤学2区 核医学2区
发表日期:2024 Sep 20
作者:
Atena Najdian, Davood Beiki, Milad Abbasi, Ali Gholamrezanezhad, Hojjat Ahmadzadehfar, Ali Mohammad Amani, Mehdi Shafiee Ardestani, Majid Assadi
DOI:
10.1186/s40644-024-00762-z
摘要
多模态成像是一种创新策略，结合了计算机断层扫描（CT）、磁共振成像（MRI）、单光子发射计算机断层扫描（SPECT）、正电子发射计算机断层扫描（PET）和光学成像（OI）等多种成像技术，实现对复杂生物过程的全面而互补的理解。这些技术的结合发挥了各自优势，克服了单一方法的局限性，显著提升了癌症诊断的准确性和治疗决策的科学性。纳米粒子具有极高的功能化潜力，可与放射性同位素和多种造影剂结合，增强信号放大、提高图像敏感性和对比度。这些定制化纳米粒子在临床前和临床应用中展现出良好的前景，既可作为成像平台，也可实现成像剂与治疗药物的协同递送，优化癌症管理策略。放射性标记纳米粒子在推动多模态成像和诊疗应用方面具有巨大潜力。本文综述了分子影像在癌症诊断中的应用、纳米技术在放射性标记材料中的最新进展，以及面临的细胞毒性和监管合规性挑战，强调了其在临床转化中的关键作用。
Abstract
Multimodal imaging unfolds as an innovative approach that synergistically employs a spectrum of imaging techniques either simultaneously or sequentially. The integration of computed tomography (CT), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and optical imaging (OI) results in a comprehensive and complementary understanding of complex biological processes. This innovative approach combines the strengths of each method and overcoming their individual limitations. By harmoniously blending data from these modalities, it significantly improves the accuracy of cancer diagnosis and aids in treatment decision-making processes. Nanoparticles possess a high potential for facile functionalization with radioactive isotopes and a wide array of contrast agents. This strategic modification serves to augment signal amplification, significantly enhance image sensitivity, and elevate contrast indices. Such tailored nanoparticles constructs exhibit a promising avenue for advancing imaging modalities in both preclinical and clinical setting. Furthermore, nanoparticles function as a unified nanoplatform for the co-localization of imaging agents and therapeutic payloads, thereby optimizing the efficiency of cancer management strategies. Consequently, radiolabeled nanoparticles exhibit substantial potential in driving forward the realms of multimodal imaging and theranostic applications. This review discusses the potential applications of molecular imaging in cancer diagnosis, the utilization of nanotechnology-based radiolabeled materials in multimodal imaging and theranostic applications, as well as recent advancements in this field. It also highlights challenges including cytotoxicity and regulatory compliance, essential considerations for effective clinical translation of nanoradiopharmaceuticals in multimodal imaging and theranostic applications.